NCT03985410

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

A Randomized, Three Period Crossover Thorough QT (TQT) Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Entasis Therapeutics · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is being conducted to evaluate the effects of supratherapeutic ETX2514 plasma concentrations on the heart rate-corrected QT interval (QTc).

Conditions

• Acinetobacter Baumannii-calcoaceticus Complex Infections

Interventions

Type	Name	Description
DRUG	ETX2514	intravenous infusion
DRUG	Placebo	intravenous infusion
DRUG	moxifloxacin	oral tablet

Timeline

• Start date: 2019-05-23
• Primary completion: 2019-07-24
• Completion: 2019-07-24
• First posted: 2019-06-13
• Last updated: 2019-08-30

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study